BridgeMD
Compares treatment options for Nocturnal Enuresis in Children
Official title Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE
ClinicalTrials.gov ID: NCT07199894
What this study is testing
What is Mirabegron (beta3-adrenoceptor agonist), Anticholinergics?
Mirabegron (beta3-adrenoceptor agonist), Anticholinergics is an investigational medicine, given as a monthly, being studied as a potential treatment for nocturnal enuresis in children.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to compare combination of Solifenacin and MIrabegron in treatment of primary mono-symptomatic nocturnal enuresis in children. It will also learn about the safety of that combination.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 6 to 18
You may be able to join if
- Primary mono-symptomatic nocturnal enuresis -
You likely can't join if
- Bowel dysfunction Psychatric illness Respiratory sleep disorders
The study team makes the final eligibility decision.
Where it's taking place
- Al Mansurah, Egypt
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 6 years to 18 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Al Mansurah, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.